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Congenital Hyperinsulinism is a condition with a number of genetic causes, but for the majority of patients, the
underlying aetiology is unknown. We present here a rational argument for the use of computational biology as a
valuable resource for identifying new candidate genes which may cause disease and for understanding the
complex mechanisms which define the pathophysiology of this rare disease.Letter
Congenital Hyperinsulinism (CHI) is a rare disease, but
is the most common cause of recurrent hypoglycaemia
in infancy [1]. The treatment of CHI can be difficult and
involves drugs which may not be successful and often are
poorly tolerated. As a potentially life-threatening condi-
tion, CHI is associated with lifelong sequelae - including
critical brain damage (epilepsy, cerebral palsy and
neurological impairment) in up to 40% of cases. To date,
nine candidate genes associate with CHI, but for the
majority of patients – estimated to be approximately
65%, both the aetiology of the CHI and the mechanisms
of disease are unknown.
Our current approach to the classification and treat-
ment of CHI is based largely upon observational correla-
tions between the pathological analysis of candidate
gene defects and clinical symptoms of hypoglycaemia
[1-3]. In this respect, there are similarities between CHI
and many other diseases in which numerous mutations
in different genes give rise to clinical phenotypes that
are essentially indistinguishable from one another. How-
ever, under normal physiological conditions, cells function
correctly because there is a high degree of interdependency
between individual biochemical components (DNA, RNA,
proteins and metabolites) and their complex interactions
(DNA-protein interactions, protein-protein interactions,
metabolic and biochemical pathways, etc.), and tissues
function in a co-ordinated manner because there is* Correspondence: mark.j.dunne@manchester.ac.uk
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reproduction in any medium, provided the orinterplay between different cell types. Diseases rarely result
from an abnormality in a single gene, but are in fact the
manifestation of disturbances in the multiple networks that
integrate cellular processes, and those that link cells with
tissues, and tissues with organ systems. As a result, current
approaches to molecular diagnosis, however valuable, have
shortcomings. These include a lack of sensitivity in identi-
fying preclinical disease, a poor ability to predict prognosis,
and ambiguity in defining and resolving a condition where
several clinical phenotypes can be observed. All of these in-
adequacies are evident in CHI, with our current under-
standing of the causes of disease failing to distinguish
transient from persistent disease at the point of presenta-
tion and to determine accurately the severity of disease.
Also, it is not possible to identify at diagnosis which
patients require curative surgery from those who could be
successfully managed by short or long-term medical ther-
apy. For these reasons we believe an innovative approach to
CHI is required – one which can identify new causes and
new mechanisms of dysfunction. One such approach is the
use of network biology, first to summate the various inter-
actions and interdependencies between gene networks, and
second to identify critical components and pathways which
may contribute to the pathophysiology of CHI.
Today, a number of diseases are being redefined through
the combination of contemporary molecular techniques
(e.g. expression arrays, epi/genomic analysis, proteomic and
metabolomics analysis) and bioinformatics to describe the
interconnected networks that govern normal cellular func-
tion and are involved in the pathophysiology of disease
[4-6]. First published in 2007, the “human disease network”l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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not only alters the product that it encodes, but also changes
the activity of the network to which it belongs [7]. This
change in activity can spread along intra- and intercellular
links of a network of interconnectivity and in doing so it
will also alter the activity of genes or other biochemical
products that otherwise carry no abnormalities [7,8]. A
consequence of this widely-held hypothesis is that the in-
terdependencies among molecular components will form
strong functional and causal relationships which can be
used to map diseases in the form of “disease networks”.
With an estimated excess of 100,000 “nodes” representing
genes, RNA, proteins, and metabolites, and an even higher
number of “links” representing the functionally-relevant
interactions between the nodes (including DNA-protein
interactions, DNA-chemical interactions, protein-protein
interactions, metabolic / biochemical pathways, etc.), the
scale and complexity of this network – the “human inter-
actome”, is daunting. However, many emerging studies
now describe how signature changes in the expression or
activities of nodes as a consequence of disease can be
integrated within the human interactome and that this re-
lationship can then be used to unlock some of the com-
plexities of pathophysiology [4-8]. With this in mind, we
have recently analysed the bioinformatics of the nineFigure 1 Human interactome network analysis of CHI-associated gene
infer a network from the BioGRID model of the human interactome (http:/
network module has been colour coded for clarity and listed separately in
inferred network was generated using the BioGRID plugin (version 3.1.94) f
genes from all known physical and genetic evidence. The CHI gene associa
imported into the Reactome Plugin for Cytoscape and modularity was anaknown CHI-causing genes – which range from transcrip-
tion factors to metabolic enzymes and solute transporters.
This was performed by generating an interaction net-
work seeded by the known CHI-associated genes (GLUD,
SLC16A1, HADH, UCP2, KCNJ11, ABCC8, HNF1A, GCK,
HNF4A) and their physical and genetic interactors as
identified using the BioGRID interactome model [9].
Surprisingly, we found that this diverse range of genes
will form a core network – described here as the CHI-
Disease Network, composed of highly connected mem-
bers, Figure 1. There is increasing evidence that the
functions associated with a biological network correlate
with modular structure within the network [10]. We
therefore assessed the presence of modularity in the
derived CHI related network using spectral-partition
clustering [11] and assessed known biological pathways
present in these modules, Table 1.
This is the first analysis of its kind for CHI or any
other monogenic disorder of glucose-regulation in in-
fancy or childhood (e.g. neonatal diabetes mellitus,
MODY, etc.). From here, we are now in a position to
explore the possibility that genes integral to the net-
work or tightly connected to it, may be new candidates
for the aetiology of CHI and other monogenic causes of
glucose-regulation disorders. Furthermore, by analysis ofs. (A) Genes with a known association with CHI in red were used to
/thebiogrid.org/). (B) Biological pathway ontology associated with each
Table 1; hypergeometric test false discovery rate (FDR) ≤ 0.001. The
or Cytoscape (version 2.8.3) to identify the primary interactors of CHI
ted network inferred from the BioGRID interactome model was then
lysed using spectral partition clustering [11].
Table 1 Pathway ontology associated with the CHI disease network
Network module Biological pathway FDR
Cellular Signalling Tropomyosin Receptor Kinase Signalling 5.0 × 10-5
RAF/MAP Kinase Cascade 5.3 × 10-5
Neurotrophin Signalling 5.9 × 10-5
mTOR Signalling 6.3 × 10-5
Syndecan-1-mediated Signalling 4.0 × 10-4
TRAIL Signalling 3.0 × 10-4
Nuclear Signalling Regulation of SMAD2/3 Signalling 1.0 × 10-4
Oestrogen Receptor-α Signalling 1.1 × 10-4
Oestrogen Receptor-β Signalling 1.5 × 10-4
Retinoic Acid Receptor Signalling 1.4 × 10-4
Growth Factor Signalling BARD1 Signalling Events 1.3 × 10-4
p53 Signalling pathway 2.0 × 10-4
HDAC Class III Signalling 1.0 × 10-3
TGFβ Signalling 2.6 × 10-4
Development ErbB2/ErbB3 Signalling 6.6 × 10-3
Presenilin Signalling 9.0 × 10-3
GMCSF-Mediated Signalling 6.6 × 10-3
Function Integration of Energy Metabolism 1.0 × 10-3
Five network modules associate with the CHI Disease Network (Figure 1) and each module has nodes which are represented in a number of canonical biological
pathways (www.ncbi.nlm.nih.gov/biosystems/). Several of these have been highlighted for each module along with their False Discovery Rate (FDR) which
represents the chance occurrence of nodes being co-located with pathways.
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listed in Table 1, we have created a portal to identify
novel mechanisms of disease which may provide insights
for the management and treatment of CHI. We strongly
believe that these in silico techniques involving access to
readily available databases are highly applicable to many
rare diseases, and that when used alone or in combination
with other datasets – e.g. metabolomic, they will form the
future basis of identifying of new candidate gene defects,
and understanding the pathophysiology of rare diseases.
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